Press Releases

GenVivo Latest News

GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors

GEN2’s dose-escalation trial, GVO-1102, will establish the Recommended Phase 2 Dose (RP2D), followed...

Read More >

GenVivo to Present Pipeline Programs at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

A new non-integrating retrovector for systemic gene delivery for multiple applications and pseudotyped...

Read More >

GenVivo to Present at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Presentations characterize GenVivo’s targeting vector development and safety data from a Phase 1...

Read More >

GenVivo to Present at the 2024 BioProcess International (BPI) US West Annual Meeting

Posters characterize GenVivo’s enveloped vector production and efforts to optimize production through...

Read More >

GenVivo to Present at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Posters characterize GenVivo’s immunotherapeutic IL-12 vectors and detail IL-12 vector (GEN-1018)...

Read More >

GenVivo to Present at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Non-Replicating, Non-Integrating Vectors, Vector Production using Continuous Perfusion Bioprocessing and...

Read More >